Initiative for medicines access & knowledge

See more. The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global (c)3 organization that advocates in the public interest for affordable access to medicines, and a medicines system that is more inclusive of patients and the public. challenge systemic injustice and advocate for health equity in drug development and access. Building a more just and equitable medicines system for all. The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global (c)3 organization that advocates in the public interest for affordable access to medicines, and a medicines system that is more inclusive of patients and the public. The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global (c)3 organization that advocates in the public interest for affordable access to medicines, and a medicines system that is more inclusive of patients and the public. [2] Contents 1 Organization 2 Past activities 3 Current activities 4 References. The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a is a U.S.-based global (c)3 organization that advocates in the public interest for affordable access to medicines, [1] and a medicines system that is more inclusive of patients and the public. I-MAK has a vision for a world in which people are able to get lifesaving medicines without excessive individual or social cost. As veterans of . Initiative for Medicines, Access and Knowledge. The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global (c)3 organization that advocates in the public interest for.

  • As veterans of the global access to medicines movement for nearly 20 years, I-MAK have created a framework that integrates deep analytical research, stakeholder informed collaboration, and a voice in the media to activate change through education. Initiative for Medicines, Access and Knowledge. I-MAK has a vision for a world in which people are able to get lifesaving medicines without excessive individual or social cost.
    • As veterans of the global access to medicines movement for nearly 20 years, I-MAK have created a framework that integrates deep analytical research, stakeholder informed collaboration, and a voice in the media to activate change through education. Initiative for Medicines, Access and Knowledge. I-MAK has a vision for a world in which people are able to get lifesaving medicines without excessive individual or social cost. Scientific breakthroughs may lead to drug. We challenge systemic injustice and advocate for health equity in drug development and access. Millions of lives are lost because of an unjust system that prevents those most vulnerable from getting the medicines they need. Why Now is the Time. We all deserve a medicines system that protects equally. I-MAK is a team of lawyers and scientists increasing access to affordable medicines by making sure the patent system reuther-hartmann.de at I-MAK believe:The patent system was designed to . In , I-MAK was established as a I-MAK envisions a world in which lifesaving medicines are readily available without excessive individual or social cost. Overpatented: Key Findings Report. Study highlights excessive patenting practices on blockbuster drugs, such as Revlimid, Humira and Enbrel, which impact cancer and arthritis. A simple and easy resource that provides patent, pricing, spending, and market data for the ten top selling drugs in America. Top Selling Drugs Data Summary. Study highlights excessive patenting practices on blockbuster drugs, such as Revlimid, Humira and Enbrel, which impact cancer and arthritis. Overpatented: Key Findings Report. Top Selling Drugs Data Summary. A simple and easy resource that provides patent, pricing, spending, and market data for the ten top selling drugs in America. Issue Areas. As veterans of the global access to medicines movement for nearly 20 years, I-MAK have created a framework that integrates deep analytical research, stakeholder informed collaboration, and a voice in the media to activate change through education. Jun 13,  · INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE (I-MAK), INC. is an Inactive company incorporated on June 13, with the registered number F . i-mak. We are a team of lawyers, scientists, and health experts challenging systemic injustice and advocating for health equity in drug development and access. Grantee Initiative for Medicines, Access & Knowledge, Inc. Location Grant Amount $50, Term Initiative for Medicines, Access & Knowledge, Inc. Grant Information Purpose To support efforts to provide key stakeholders and policymakers nonpartisan technical assistance and educate the public about drug patents and high drug prices. Grantee Initiative for Medicines, Access & Knowledge, Inc. Location Grant Amount $50, Term Initiative for Medicines, Access & Knowledge, Inc. Grant Information Purpose To support efforts to provide key stakeholders and policymakers nonpartisan technical assistance and educate the public about drug patents and high drug prices. Grantee Initiative for Medicines, Access & Knowledge, Inc. Location Grant Amount $50, Term Grant Initiative for Medicines, Access & Knowledge, Inc. Grant Information Purpose To support efforts to provide key stakeholders and policymakers nonpartisan technical assistance and educate the public about drug patents and high drug prices. . Jul 04,  · initiative for medicines, access & knowledge (i-mak) I-MAK is an initiative to bring new and practical perspectives to issues impacting medicines, access and knowledge. Co-founded in by Priti Krishtel and Tahir Amin, I-MAK (Initiative for Medicines, Access & Knowledge) is a nonprofit that challenges systemic injustice. By making clinical trial data available, it would not only help save lives but also make the search for new medicines more efficient and less costly.”. “From the cost of R&D for a drug right through to its clinical trial data, there is a serious lack of transparency in the current system which only benefits the pharmaceutical companies. By making clinical trial data available, it would not only help save lives but also make the search for new medicines more efficient and less costly.”. “From the cost of R&D for a drug right through to its clinical trial data, there is a serious lack of transparency in the current system which only benefits the pharmaceutical companies. By making clinical trial data available, it would not only help save lives but also make the search for new medicines more efficient and less costly.". "From the cost of R&D for a drug right through to its clinical trial data, there is a serious lack of transparency in the current system which only benefits the pharmaceutical companies. Initiative for Medicines Access & Knowledge I-Mak Inc. is a (c)(3) organization, with an IRS ruling year of , and donations are tax-deductible. I-MAK is a team of lawyers and scientists increasing access to affordable medicines by making sure the patent system reuther-hartmann.de at I-MAK believe:The patent system was designed to balance innovation in Also known as I-Mak) Inc Total revenues $, Total expenses $, Total assets $1,, Num. employees 4 I-MAK is a team of lawyers and scientists increasing access to affordable medicines by making sure the patent system reuther-hartmann.de at I-MAK believe:The patent system was designed to balance innovation in Also known as I-Mak) Inc Total revenues $, Total expenses $, Total assets $1,, Num. employees 4 I-MAK is a team of lawyers and scientists increasing access to affordable medicines by making sure the patent system reuther-hartmann.de at I-MAK believe:The patent system was designed to balance innovation in Also known as I-Mak) Inc Total revenues $, Total expenses $, Total assets $1,, Num. employees 4 Initiative for Medicines, Access and Knowledge I-MAK has a vision for a world in which people are able to get lifesaving medicines without excessive.
  • Initiative for Medicines Access & Knowledge I-Mak Inc. reported its largest program on its FY Form as: $, Spent in most recent FY % Percent of program expenses IN , I-MAK'S PUBLIC EDUCATION PROGRAMMING WORKED TOWARDS THE GOAL OF MAKING THE ROLE OF PATENTS CENTRAL IN THE DRUG PRICING CONVERSATION.
    • An Introduction to Access to Generic Hepatitis C Medicines. Access Initiative (CHAI) Antiretroviral (ARV) CHAI Reference Price List. 1 November Available: reuther-hartmann.de). For generic SOF, we used the current market price produced by leading suppliers in India (World Hepatitis Alliance. - · LJAF · $50, · To support. To support efforts to provide patients with affordable access to life-saving medications and improve public health. Contact Information reuther-hartmann.de COASTAL HWY Lewes DE Access the Nonprofit Portal to submit data and download your rating toolkit. Initiative for Medicines Access & Knowledge I-Mak Inc. is a (c) (3) organization, with an IRS ruling year of , and donations are tax-deductible. Is this your nonprofit? International Taxpayers. Individuals abroad and more. For you and your family. Read the report to see. Our Scorecard ranks every state's health care system based on how well it provides high-quality, accessible, and equitable health care. ACRONYMS. 2. Initiative for Medicines Access & Knowledge. A2M ACCESS TO MEDICINES ABC ABACAVIR SULFATE (ZIAGEN®) ARV ANTIRETROVIRAL DAC DACLATASVIR (DAKLINZA®) DNP+ DELHI NETWORK OF POSITIVE PEOPLE (INDIA) EPO EUROPEAN PATENT OFFICE ETR ETRAVIRINE (INTELENCE®) HCV HEPATITIS C VIRUS HPV HUMAN PAPILLOMAVIRUS I-MAK INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE LED LEDIPASVIR (WITH SOFOSBUVIR IN HARVONI®) LMICS LOW- AND MIDDLE-INCOME COUNTRIES. Annual Report. Thanks! Initiative for Medicines, Access & Knowledge (I-MAK) 25 August Our website is now up at reuther-hartmann.de We are pleased to announce that the Initiative for Medicines, Access & Knowledge (I-MAK) website is now up and accessible through reuther-hartmann.de All our current and future work will be available at reuther-hartmann.de from now on.